Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Immunoglobulin light chain amyloidosis (AL) should be considered in any patient that presents to a cancer care provider with nephrotic range proteinuria, heart failure with preserved ejection fraction, non-diabetic peripheral neuropathy, unexplained hepatomegaly or diarrhea. More importantly, patients being monitored for smoldering multiple myeloma and a monoclonal gammopathy of undetermined significance (MGUS) are at risk for developing AL amyloidosis. MGUS and myeloma patients that have atypical features, including unexplained weight loss; lower extremity edema, early satiety, and dyspnea on exertion should be considered at risk for light chain amyloidosis. Overlooking the diagnosis of light chain amyloidosis leading to therapy delay is common, and it represents an error of diagnostic consideration. Algorithms will be provided on how to evaluate patients with suspected AL amyloid as well as how to manage patients referred from other medical specialties with biopsy-proven amyloid. An organized stepwise approach to the treatment of patients with light chain amyloidosis, including established and investigational therapies, will be reviewed.

Original languageEnglish (US)
Article number80
JournalBlood Cancer Journal
Volume8
Issue number5
DOIs
StatePublished - May 1 2018

Fingerprint

Immunoglobulin Light Chains
Amyloidosis
Monoclonal Gammopathy of Undetermined Significance
Light
Amyloid
Therapeutics
Investigational Therapies
Hepatomegaly
Peripheral Nervous System Diseases
Diagnostic Errors
Multiple Myeloma
Proteinuria
Dyspnea
Weight Loss
Lower Extremity
Diarrhea
Edema
Heart Failure
Medicine
Biopsy

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018. / Gertz, Morie.

In: Blood Cancer Journal, Vol. 8, No. 5, 80, 01.05.2018.

Research output: Contribution to journalArticle

@article{2721dabc7aa54dd0aad89e337a7fa437,
title = "Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018",
abstract = "Immunoglobulin light chain amyloidosis (AL) should be considered in any patient that presents to a cancer care provider with nephrotic range proteinuria, heart failure with preserved ejection fraction, non-diabetic peripheral neuropathy, unexplained hepatomegaly or diarrhea. More importantly, patients being monitored for smoldering multiple myeloma and a monoclonal gammopathy of undetermined significance (MGUS) are at risk for developing AL amyloidosis. MGUS and myeloma patients that have atypical features, including unexplained weight loss; lower extremity edema, early satiety, and dyspnea on exertion should be considered at risk for light chain amyloidosis. Overlooking the diagnosis of light chain amyloidosis leading to therapy delay is common, and it represents an error of diagnostic consideration. Algorithms will be provided on how to evaluate patients with suspected AL amyloid as well as how to manage patients referred from other medical specialties with biopsy-proven amyloid. An organized stepwise approach to the treatment of patients with light chain amyloidosis, including established and investigational therapies, will be reviewed.",
author = "Morie Gertz",
year = "2018",
month = "5",
day = "1",
doi = "10.1038/s41408-018-0080-9",
language = "English (US)",
volume = "8",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018

AU - Gertz, Morie

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Immunoglobulin light chain amyloidosis (AL) should be considered in any patient that presents to a cancer care provider with nephrotic range proteinuria, heart failure with preserved ejection fraction, non-diabetic peripheral neuropathy, unexplained hepatomegaly or diarrhea. More importantly, patients being monitored for smoldering multiple myeloma and a monoclonal gammopathy of undetermined significance (MGUS) are at risk for developing AL amyloidosis. MGUS and myeloma patients that have atypical features, including unexplained weight loss; lower extremity edema, early satiety, and dyspnea on exertion should be considered at risk for light chain amyloidosis. Overlooking the diagnosis of light chain amyloidosis leading to therapy delay is common, and it represents an error of diagnostic consideration. Algorithms will be provided on how to evaluate patients with suspected AL amyloid as well as how to manage patients referred from other medical specialties with biopsy-proven amyloid. An organized stepwise approach to the treatment of patients with light chain amyloidosis, including established and investigational therapies, will be reviewed.

AB - Immunoglobulin light chain amyloidosis (AL) should be considered in any patient that presents to a cancer care provider with nephrotic range proteinuria, heart failure with preserved ejection fraction, non-diabetic peripheral neuropathy, unexplained hepatomegaly or diarrhea. More importantly, patients being monitored for smoldering multiple myeloma and a monoclonal gammopathy of undetermined significance (MGUS) are at risk for developing AL amyloidosis. MGUS and myeloma patients that have atypical features, including unexplained weight loss; lower extremity edema, early satiety, and dyspnea on exertion should be considered at risk for light chain amyloidosis. Overlooking the diagnosis of light chain amyloidosis leading to therapy delay is common, and it represents an error of diagnostic consideration. Algorithms will be provided on how to evaluate patients with suspected AL amyloid as well as how to manage patients referred from other medical specialties with biopsy-proven amyloid. An organized stepwise approach to the treatment of patients with light chain amyloidosis, including established and investigational therapies, will be reviewed.

UR - http://www.scopus.com/inward/record.url?scp=85047405808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047405808&partnerID=8YFLogxK

U2 - 10.1038/s41408-018-0080-9

DO - 10.1038/s41408-018-0080-9

M3 - Article

VL - 8

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 5

M1 - 80

ER -